Holen Sie sich die Stockscreener-App
3.74
2.75%
0.10
Handel nachbörslich:
3.74
Omeros Corporation Aktie (OMER) Neueste Nachrichten
What analysts say about Omeros Corporation stockPhenomenal wealth increase - jammulinksnews.com
What drives Omeros Corporation stock priceTremendous wealth creation - jammulinksnews.com
Why Omeros Corporation stock attracts strong analyst attentionAnalyst Grade Signals - Newser
Is Omeros Corporation a good long term investmentSky-high profits - PrintWeekIndia
Omeros Corporation Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
How Omeros Corporation stock performs during market volatilityStrategic High Profit Opportunities - beatles.ru
what makes omeros corporation stock price move sharplyFree Access to Community - Newser
FY2027 Earnings Forecast for Omeros Issued By HC Wainwright - Defense World
What makes Omeros Corporation stock price move sharplyWatchlist Winner Update - Newser
Omeros Corporation (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Wealth Enhancement Advisory Services LLC Takes $579,000 Position in Omeros Corporation (NASDAQ:OMER) - Defense World
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost - MSN
Both retail investors who control a good portion of Omeros Corporation (NASDAQ:OMER) along with institutions must be dismayed after last week's 12% decrease - simplywall.st
Omeros shareholders elect directors and approve executive pay at annual meeting - Investing.com
Omeros stock maintains Buy rating at H.C. Wainwright on EU submission - Investing.com
Omeros (NASDAQ:OMER) Downgraded by Wall Street Zen to “Sell” - Defense World
Omeros' Narsoplimab: A Lifeline for TA-TMA Patients and a Regulatory Crossroads - AInvest
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA | OMER Stock News - GuruFocus
Omeros (OMER) Eyes European Approval for Key Drug Narsoplimab | OMER Stock News - GuruFocus
Omeros Announces Webcast Details for Annual Meeting of Shareholders - The Joplin Globe
Ratios Revealed: Decoding Omeros Corporation (OMER)’s Financial Health - DWinneX
Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
What is HC Wainwright’s Forecast for Omeros FY2025 Earnings? - Defense World
HC Wainwright Predicts Omeros’ Q2 Earnings (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Now Covered by Analysts at HC Wainwright - Defense World
Cantor Fitzgerald Comments on Omeros FY2026 Earnings - Defense World
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
Trend Tracker for (OMER) - news.stocktradersdaily.com
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OME - GuruFocus
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OMER Stock News - GuruFocus
HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target - MarketScreener
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval - GuruFocus
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval | OMER Stock News - GuruFocus
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - mx.advfn.com
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - Defense World
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 - mx.advfn.com
OMEROmeros Corporation Reports First Quarter 2025 Financial Results - mx.advfn.com
Squarepoint Ops LLC Has $316,000 Stake in Omeros Co. (NASDAQ:OMER) - Defense World
Millennium Management LLC Buys 27,088 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):